Aminoglycoside penetration, inactivation, and efficacy in XXXX sputum.

@entity1 @entity796 @entity2890 @entity3405 @entity581 @entity1577
We studied sputum @entity2890 concentrations after intravenous administration in 10 @entity1577 @entity1 . @entity2890 concentrations were determined by a bioassay and a radioenzymatic assay (REA). The bacterial density of @entity796 in sputum was examined serially during therapy. Bioactivity of @entity2890 in the sputum was low and increased little during treatment. In contrast, @entity2890 content (as assayed by REA) showed a progressive accumulation of the drug to high concentrations: a mean of 82 micrograms/g sputum after 3 wk of therapy in 4 @entity1 . @entity796 was eradicated from the sputum in 3 of 4 patients receiving antibiotic therapy for 3 wk. Eradication correlated with @entity2890 sputum concentrations measured by REA, which were 20-fold greater than the apparent @entity2890 inhibitory concentration. A bactericidal effect of @entity581 in the presence of sputum in vitro could only be reliably produced with concentrations 25-fold the MIC. We conclude that @entity2890 penetrates @entity1577 ( @entity1577 ) sputum and accumulates over time. Although @entity1577 sputum antagonized the bioactivity of @entity581 , 3 wk of intravenous therapy combined with an antipseudomonal @entity3405 antibiotic may be effective in eradication of @entity796 from sputum of certain @entity1577 @entity1 .
